Izzy

“You know, it's been a couple months since you have stepped back into the CEO role here at Integra, and I was curious what you have seen in that time that has kind of been in line with your expectations and if there has been anything that maybe you didn't expect.”

“I was hoping you guys could spend some time talking about what you're seeing in the orthobiologic I'm mostly curious about where your underlying unit growth is and how that's tracking relative to the broader market.”

“So I just wanted to start on your ASP and mixed shift. Mark, it sounded like you are expecting the ASP headwinds to lapse around the fourth quarter, but I was hoping you could speak to that a little bit more and what we can expect moving throughout the year.”

“Just to start, Nick, you touched on this to an earlier question, but I was hoping you could speak a little bit more about the segmentation that you're seeing in the market for cartilage lesions between Macy and other two-step procedures in terms of the lesion type, anatomical segmentation, grade levels, etc.”

“And then I saw the press release today and heard your comments about the launch of Traxio. So I was hoping you guys could talk a little bit more about your plans there for the rollout and what we can look forward to going forward.”